The outcomes of BCR::ABL+ B-ALL have dramatically improved in recent years due to the introduction of BCR::ABL-targeting TKIs and antibodies, including the bispecific monoclonal antibody blinatumomab and the conjugated antibody inotuzumab ozogamicin, either frontline, in combination with classical chemotherapy, or in relapsed and refractory disease [1]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.